Skip to main content

Advertisement

Table 4 Overall response rate and PFS in 5 randomized trials comparing gemcitabine to gemcitabine plus platinum analog

From: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer

Reference Year n Treatment regimen ORR (%) p Median PFS/TTP (mo) p
Louvet 2005 156 Gemcitabine 17.3 0.04 3.7 0.04
   157 Gemcitabine (FDR) + Oxaliplatin 26.8   5.8  
Poplin 2006 279 Gemcitabine (standard) 5 -- na na
   277 Gemcitabine (FDR) 10 --   
   276 Gemcitabine (FDR) + Oxaliplatin 9 --   
Heinemann 2006 95 Gemcitabine 8.2 -- 3.1 0.053
   95 Gemcitabine + Cisplatin 10.2   5.3  
Colucci 2002 54 Gemcitabine 9.2 0.02 2.0 0.048
   53 Gemcitabine + Cisplatin 26.4   5.0  
Viret 2004 41 Gemcitabine 5 -- 2.5 ns
   42 Gemcitabine + Cisplatin 7   2.2  
  1. ORR = overall response rate; PFS = progression-free survival; TTP = time-to-progression; FDR = fixed dose rate; na = data not available; ns = not significant;